Seminars in Nuclear Medicine
Volume 38, Issue 2 , Pages S13-S18 , March 2008

Natural History of Hepatocellular Carcinoma and Current Treatment Options

  • Jean-Luc Raoul, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Jean-Luc Raoul, MD, PhD, Centre Régional de Lutte Contre le Cancer, E. Marquis, 35042 Cedex Rennes, France.

References 

  1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–1917
  2. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology. 2004;127:S27–S34
  3. El-Serag HB. Hepatocellular carcinoma: Recent trends in the United States. Gastroenterology. 2004;127:S27–S34
  4. Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126:1005–1014
  5. Bréchot C. Pathogenesis of hepatitis B virus related hepatocellular carcinoma: Old and new paradigms. Gastroenterology. 2004;127:S56–S61
  6. Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2004;127:S303–S309
  7. Callee EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity and mortality from cancer in a prospective studied cohort of US adults. N Engl J Med. 2003;348:1625–1638
  8. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–S50
  9. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis. 1999;19:329–338
  10. CLIP. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma. Hepatology. 2000;31:840–845
  11. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma: conclusions of the Barcelona–2000 EASL conference. J Hepatol. 2001;35:421–430
  12. Song TJ, Ip EWK, Fong Y. Hepatocellular carcinoma: Current surgical management. Gastroenterology. 2004;127:S248–S260
  13. Lau WY, Leung TW, Ho SK, et al. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial. Lancet. 1999;353:797–801
  14. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med. 1996;334:693–699
  15. Livraghi T, Giorgio A, Marin G, et al. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injections. Radiology. 1995;197:101–108
  16. Lencioni R, Allgaier HP, Cioni D, et al. Small hepatocellular carcinoma in cirrhosis: Randomized controlled trial of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228:235–240
  17. Lin SM, Lin CJ, Lin CC, et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology. 2004;127:1714–1723
  18. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization: a multicenter randomized trial. Hepatology. 2002;35:1164–1171
  19. Llovet JM, Real MI, Montana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma. Lancet. 2002;359:1734–1739
  20. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37:429–442
  21. Raoul JL, Guyader D, Bretagne JF, et al. Prospective randomized trial of chemoembolization versus intra-arterial injection of 131I-labeled-iodized oil in the treatment of hepatocellular carcinoma. Hepatology. 1997;26:1156–1161
  22. Raoul JL, Guyader D, Bretagne JF, et al. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial Iodine-131-iodized oil versus medical support. J Nucl Med. 1994;35:1782–1787
  23. Raoul JL, Boucher E, Olivie D, et al. Association of cisplatin and intra-arterial injection of 131I-lipiodol in treatment of hepatocellular carcinoma: Results of a phase II trial. Int J Radiat Oncol Biol Phys. 2006;64:745–750
  24. Sundram FX, Jeong JM, Zanzonico P, et al. Trans-arterial rhenium-188 lipiodol in the treatment of inoperable hepatocellular carcinoma: An IAEA sponsored multi-centre phase I study. World J Nucl Med. 2002;1:5–11
  25. Lambert B, Bacher K, Defreyne L, et al. 188Re-HDD/Lipiodol therapy for hepatocellular carcinoma: a phase I clinical trial. J Nucl Med. 2005;46:60–66
  26. Geschwind JFH, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127:S194–S205
  27. Ando E, Tanaka M, Yamashita F, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95:588–595
  28. Bruix J, Sherman M, Llovet JM, et al. EASL panel of experts on HCC Clinical management of hepatocellular carcinoma (Conclusions of the Barcelona-2000 EASL conference). J Hepatol. 2001;35:421–430
  29. Thomas MB, Zhu AX. Hepatocellular carcinoma: The need for progress. J Clin Oncol. 2005;23:2892–2899

 Conflict of Interest: None.

PII: S0001-2998(07)00120-1

doi: 10.1053/j.semnuclmed.2007.10.004

Seminars in Nuclear Medicine
Volume 38, Issue 2 , Pages S13-S18 , March 2008

Article Tools

* Image Usage & Resolution